HCYP2MAG-62K
MILLIPLEX® Human Cytokine/Chemokine Magnetic Bead Panel II - Immunology Multiplex Assay
Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology, in human serum, plasma and cell culture samples.
Synonym(s):
Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84
Recommended Products
Quality Level
species reactivity
human
manufacturer/tradename
Milliplex®
assay range
accuracy: 81-110%
sensitivity: 0.4-55.8 pg/mL
standard curve range: 1.0-100,000 pg/mL
technique(s)
multiplexing: suitable
detection method
fluorometric (Luminex xMAP)
shipped in
wet ice
General description
“Cytokine” is a general term used for a diverse group of soluble proteins and peptides which act as regulators under both normal and pathological conditions to modulate the functional activities of individual cells and tissues. These proteins also mediate direct interactions between cells and regulate processes taking place in the extracellular environment. The cytokine group of proteins includes lymphokines, interferons, colony stimulating factors and chemokines. Cytokine and chemokine research plays a significant role in achieving a deeper understanding of the immune system and its multi-faceted response to most antigens, as well as disease states such as inflammatory disease, allergic reactions, irritable bowel disease (IBD), sepsis, and cancer.
The MILLIPLEX® Human Cytokine / Chemokine Panel II enables you to focus on the therapeutic potential of cytokines as well as the modulation of cytokine expression.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Cytokines/Chemokines
The MILLIPLEX® Human Cytokine / Chemokine Panel II enables you to focus on the therapeutic potential of cytokines as well as the modulation of cytokine expression.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Cytokines/Chemokines
Specificity
Cross Reactivty
There was no or negligible cross-reactivity between the antibodies and any of the other analytes in this panel.
There was no or negligible cross-reactivity between the antibodies and any of the other analytes in this panel.
Application
- Analytes: 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, I-309, IL-16, IL-20, IL-21, IL-23, IL-28A, IL-33, LIF, MCP-2, MCP-4, MIP-1δ, SCF, SDF-1A+β, TARC, TPO, TRAIL, TSLP
- Recommended Sample type: Serum, plasma, cell culture supernatant
- Recommended Sample dilution: neat
- Assay Run Time: Overnight or two-hour primary incubation. For best results, an overnight incubation is recommended
- Research Category: Inflammation & Immunology
- Research Subcategory: Obesity, Metabolic Disorders, Inflammation & Autoimmune Mechanisms
Features and Benefits
Design your multiplex kit by choosing available analytes within this panel.
Packaging
96 well plate
Storage and Stability
Recommended storage for kit components is 2 - 8°C.
Other Notes
Please contact Technical Service for linearity of dilution.
Legal Information
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
Target Organs
Respiratory Tract
Storage Class Code
10 - Combustible liquids
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Evidence of enhanced systemic inflammation in stable kidney transplant recipients with low Framingham risk scores.
Mansell, H; Rosaasen, N; Dean, J; Shoker, A
Clinical Transplantation null
Fawaz Y Azizieh et al.
Journal of inflammation research, 12, 99-108 (2019-05-24)
Objective: In addition to some well-characterized bone turnover markers (BTMs), cytokines and adipokines have also been suggested to be linked to osteoporosis seen in menopause. However, there is much controversy on the possible association between these markers and bone mineral density
Ashok Kumar Kumawat et al.
Mediators of inflammation, 2014, 879843-879843 (2014-10-22)
Soluble factors from intestinal mucosal cells contribute to immune homeostasis in the gut. We have established an in vitro model to investigate the regulatory role of soluble factors from inflamed intestinal mucosa of collagenous colitis (CC) patients in the differentiation
Yanping Tong et al.
Frontiers in neurology, 9, 44-44 (2018-03-03)
A prominent pathological feature of neuromyelitis optica spectrum disorders (NMOSD) is markedly greater eosinophilic infiltration than that seen in other demyelinating diseases, like multiple sclerosis (MS). Eosinophils express the chemokine receptor CCR3, which is activated by eotaxins (CCL11/eotaxin-1, CCL24/eotaxin-2, CCL26/eotaxin-3)
Beatriz M Carreno et al.
The Journal of clinical investigation, 123(8), 3383-3394 (2013-07-23)
Systemic administration of IL-12p70 has demonstrated clinical activity in cancer patients, but dose-limiting toxicities have hindered its incorporation in vaccine formulations. Here, we report on the immunological and clinical outcomes upon vaccination with CD40L/IFN-γ-matured, IL-12p70-producing DCs. 7 HLA-A*0201+ newly diagnosed
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service